Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
ClonOrgan logo — Pioneering the future of organ transplantation with human-co...

ClonOrgan

Pioneering the future of organ transplantation with human-compatible organs grown from gene-edited pigs through a comprehensive R&D platform since 2005.

Founded 2005 Series A Total: $16.97M Biotechnology, Health Care

General Information

Company Name ClonOrgan
Founded Year 2005
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with ClonOrgan. To contact ClonOrgan, visit clonorgan.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ClonOrgan compare?

A PDF of ClonOrgan and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ClonOrgan soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ClonOrgan

ClonOrgan is a biotechnology company that has been pioneering the future of organ transplantation since its establishment in 2005. The company's slogan, "Pioneering the future of organ transplantation with human-compatible organs grown from gene-edited pigs through a comprehensive R&D platform," encapsulates its groundbreaking approach. ClonOrgan focuses on xenotransplantation and has devised a method to humanize pig cells, thereby enabling the growth of organs compatible with human transplantation. The last investment of $6.97M Series A came from Royal Sea Capital on 03 September 2021. ClonOrgan offers a comprehensive R&D platform that spans from the cultivation of gene-edited pigs to preclinical testing and breeding. The company's mission is to address the severe shortage of organs for clinical transplantation and establish the future's organ production hub. Located in Chengdu, Sichuan, ClonOrgan is at the forefront of addressing this critical medical need. In the rapidly evolving fields of biotechnology and healthcare, ClonOrgan's innovative approach and recent investment from Royal Sea Capital demonstrate the confidence and potential in the company's vision to revolutionize organ transplantation.

Business keywords: Xenotransplantation, Organ transplantation, Gene editing, Regenerative medicine, Medical technology, Research and development, Pig organs, Human-compatible organs, Preclinical testing, Biomedical innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A CNY10.00M 1
Dingzhou Yichuang
05 Jul 2024
Series A $6.97M 1
Royal Sea Capital
03 Sep 2021

ClonOrgan Alternatives & Competitors

View All Alternatives
ClonOrgan vs
Qihan Biotechnology Co., Ltd.
Qihan Biotechnology Co., Ltd. China

A world in which cell and organ therapies are universally available to patients.

Series B
11 employees
Biotechnology, Health Care
ClonOrgan vs
Shanghai Genext Medical Technology Co., Ltd
Shanghai Genext Medical Technology Co., Ltd China

推动移植邻域的创新与发展，助理患者长期存活

Venture round
8 employees
Biotechnology, Health Care
ClonOrgan vs
Transplant Biomedicals
Transplant Biomedicals Spain

Do not risk your patients. Trust. VIVIAN takes care.

Venture round
1 employees
Biotechnology, Health Care
Also compare with: ClonOrgan vs Precise Bio Precise Bio ClonOrgan vs Spotlight Therapeutics Spotlight Therapeutics View all alternatives

FAQ About ClonOrgan

Pioneering the future of organ transplantation with human-compatible organs grown from gene-edited pigs through a comprehensive R&D platform since 2005.
ClonOrgan was founded in 2005.
ClonOrgan operates in Biotechnology and Health Care. Its work centres on Xenotransplantation, Organ transplantation, Gene editing and Regenerative medicine.
ClonOrgan has completed 2 funding rounds, raising a total of $16.97M. The latest funding stage is Series A.
Top alternatives and competitors to ClonOrgan include Qihan Biotechnology Co., Ltd., Shanghai Genext Medical Technology Co., Ltd, Transplant Biomedicals, Precise Bio, Novo Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ClonOrgan and Qihan Biotechnology Co., Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ClonOrgan, https://bouncewatch.com/company/clonorgan, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes